Adverse events60

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 60

Download this page as JSON

Type	Event	Organ system	Group	Affected	At risk
other	Diarrhoea	Gastrointestinal disorders	Nirmatrelvir (PF-07321332) 300 mg + Ritonavir 100 mg 5 Days	23	912
other	Diarrhoea	Gastrointestinal disorders	Nirmatrelvir (PF-07321332) 300 mg + Ritonavir 100 mg 10 Days	22	911
other	Diarrhoea	Gastrointestinal disorders	Placebo	15	898
other	Nausea	Gastrointestinal disorders	Nirmatrelvir (PF-07321332) 300 mg + Ritonavir 100 mg 5 Days	16	912
other	Nausea	Gastrointestinal disorders	Nirmatrelvir (PF-07321332) 300 mg + Ritonavir 100 mg 10 Days	12	911
other	Nausea	Gastrointestinal disorders	Placebo	14	898
other	Asthenia	General disorders	Nirmatrelvir (PF-07321332) 300 mg + Ritonavir 100 mg 5 Days	10	912
other	Asthenia	General disorders	Nirmatrelvir (PF-07321332) 300 mg + Ritonavir 100 mg 10 Days	7	911
other	Asthenia	General disorders	Placebo	17	898
other	COVID-19	Infections and infestations	Nirmatrelvir (PF-07321332) 300 mg + Ritonavir 100 mg 5 Days	27	912
other	COVID-19	Infections and infestations	Nirmatrelvir (PF-07321332) 300 mg + Ritonavir 100 mg 10 Days	26	911
other	COVID-19	Infections and infestations	Placebo	36	898
other	Nasopharyngitis	Infections and infestations	Nirmatrelvir (PF-07321332) 300 mg + Ritonavir 100 mg 5 Days	13	912
other	Nasopharyngitis	Infections and infestations	Nirmatrelvir (PF-07321332) 300 mg + Ritonavir 100 mg 10 Days	9	911
other	Nasopharyngitis	Infections and infestations	Placebo	6	898
other	Upper respiratory tract infection	Infections and infestations	Nirmatrelvir (PF-07321332) 300 mg + Ritonavir 100 mg 5 Days	20	912
other	Upper respiratory tract infection	Infections and infestations	Nirmatrelvir (PF-07321332) 300 mg + Ritonavir 100 mg 10 Days	17	911
other	Upper respiratory tract infection	Infections and infestations	Placebo	18	898
other	Activated partial thromboplastin time prolonged	Investigations	Nirmatrelvir (PF-07321332) 300 mg + Ritonavir 100 mg 5 Days	11	912
other	Activated partial thromboplastin time prolonged	Investigations	Nirmatrelvir (PF-07321332) 300 mg + Ritonavir 100 mg 10 Days	14	911

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05047601/events

API reference For AI assistants

Adverse events60

Sources 3

Read this list from software.